PrEP acronym (pre-exposure prophylaxis)

Phase 3Small molecule

PrEP acronym (pre-exposure prophylaxis) is one of 6 small molecule programs targeting Alcohol. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AlcoholRecruiting

AlcoholPhase 3

Recruiting

Competition

Competitive Landscape

5 competitors in Alcohol

#DrugCompanyPhaseTrials

Alcohol

Astellas

Phase 2

14 2

Benemid

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

1 3

Belsomra

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 1

1 4

PrEP acronym (pre-exposure prophylaxis)

UUniversity of Florida

Phase 3

1 5

Azulfidine

Pfizer

Preclinical

1 6

Glutathione

UUniversity of Chicago

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Alcohol1 trial

ANCHORS Alcohol & Sexual Health Study: UH3 Project

Recruiting·UUniversity of Florida·Phase 4·NCT04331704·88 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for PrEP acronym (pre-exposure prophylaxis). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PrEP acronym (pre-exposure prophylaxis) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PrEP acronym (pre-exposure prophylaxis). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Florida company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Florida

PrEP acronym (pre-exposure prophylaxis)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Alcohol1 trial

References

Drug Info

Quick Facts

Related News